

# Fund Profile

## Our Objective

Mammoth Scientific’s objective is to generate top quartile returns through the long-term capital appreciation of investments in private companies. These investments will be structured as equity, convertible securities and other equity-related investments in the healthcare and information technology sectors, and are expected to include portfolio companies specializing in medical devices, infrastructure, information technology, financial technology, biotechnology, wellness and life sciences.

## At a Glance

Target Fund Size    **~\$100 Million**

Investment Term    **10+1+1**

Management Fee    **1.9 - 2% (first 5 years)**  
**0% (year 6+)**

Carried Interest    **25%**  
**above your returned fee & capital**

Admin Fee    **\$399/year per investor (year 2+)**  
billed directly to investors each April/May

Easy VC entry point for investments <\$250k  
ROI timing enhancement for investments >\$250k

## How We Expect to Win

### Pathways

To achieve successful outcomes in health science and technology, innovation has to move beyond ideas by creating pathways for both reimbursement and regulatory approval. We expect to add value from our deep functional understanding of

- healthcare delivery,
- contracting,
- private and CMS reimbursement,
- creation of new CMS reimbursement pathways, and
- FDA and EU regulatory requirements.

### Networks


Through strong relationships with leading physician, surgeon, healthcare executives and global thought leaders, we help founders create new avenues for profitability. We are also well connected with the senior management of many of the largest healthcare companies as well as private and institutional investors.

### Advantages

Our knowledge, experience, and networks are anticipated to provide us with key advantages: early looks at promising companies, strategies to navigate regulatory pathways, and participation in syndications with leading venture investors.

## Selecting Portfolio Companies

We find complex companies who are solving big problems, specifically those who are solving complex:



## 4 Key Traits that Set Our Portfolio Companies Apart

We seek outsized returns for our Fund Members by investing early in companies that:

1. fill an unserved gap or unmet need in healthcare and life sciences, not merely a preference based product or service.
2. have a clear time and cost efficient pathway to both FDA and EU clearance as well as public and private reimbursement approval processes.
3. have founder teams with healthcare and tech experience who are post revenue generation.
4. fit into a healthcare delivery and regulatory community where Mammoth can directly accelerate growth and facilitate exit strategies and exit partners.

When You're Ready to **Invest Beyond the Ordinary™**

Contact us to set up a call.

Email: [hello@mammothresearch.com](mailto:hello@mammothresearch.com)

Phone: (800) 618-2299

Mammoth Scientific, LLC is an investment adviser to venture capital funds that files as an exempt reporting adviser. Status as an exempt reporting adviser does not imply a certain level of skill or training. Private companies and private investments involve unique risks. You should be aware that you could lose your entire investment.

Atlanta, GA | Charleston, SC | Charlotte, NC | Fort Wayne, IN | Metro Detroit, MI  
(800) 618-2299

## How Investment as a Fund Member Works

When you invest in Mammoth Health and Tech Fund 1, you become a Member of the Fund. That means that you own shares in the Fund which gives you an economic interest related to the Fund's profits and losses. The Fund uses its Members' investments to purchase interests in the health, life science and tech companies that will be the Fund's Portfolio Companies.

Your liability related to the Fund is limited to the potential loss of your investment. You have no personal liability above the amount you invest. Mammoth Scientific as the Fund's Manager is responsible for the daily operations and general management of the Fund. The Members do not participate in management or operations.

The Fund invests in companies who we believe will experience a liquidity event large enough to return your original capital investment plus a healthy gain. There is no guarantee of this result but that is the Investment Objective. The Fund is intended to invest, directly or indirectly, in a diverse range of early, expansion, and late-stage portfolio companies. We anticipate that the Fund may invest in between 5-15 portfolio companies at the discretion of Mammoth Scientific.

A liquidity event may be in the form of a sale, merger, initial public offering or similar. Mammoth deliberately selects portfolio companies with exit strategies anticipated to be about 5 years.

## Important Legal Disclosure

This document is provided to potential investors to assist in evaluating participation in the opportunity described in it. This is not an offering document. Any offer of securities in a Mammoth Fund may only be made by delivery by Mammoth Scientific, LLC to the potential investor of definitive offering and legal documents. Mammoth Scientific, LLC is an investment adviser to venture capital funds that files as an exempt reporting adviser. Status as an exempt reporting adviser does not imply a certain level of skill or training. The securities offered by Mammoth Scientific, LLC have not been registered under the Securities Act of 1933, as amended, or the securities laws of any state, or jurisdiction, in reliance upon the exemptions from registration provided by the Securities Act and Regulation D Rule 506 (c) and comparable exemptions from registration provided by other applicable securities laws.

Dr. Jay Yadav is a Member of MiRus, LLC and serves as its Chief Executive Officer. Dr. Yadav is also a Member of Mammoth Investors, LLC (“Mammoth”). He serves on the board of Mammoth as a voting director and serves as the Chief Investment Officer. Mammoth has put in place and follows conflict of interest policies for all Board Members.

This document contains forward-looking statements or projections. These forward-looking statements can be identified by use of forward-looking terminology such as “may”, “will”, “should”, “expect”, “anticipate”, “project”, “estimate”, “intend”, “continue,” or “believe,” or the negatives thereof or comparable terminology. Due to various risks and uncertainties, actual events, results or the actual performance of the Mammoth Fund’s portfolio companies may differ materially from those reflected or contemplated in such forward-looking statements. Nothing contained in this document may be relied upon as a guarantee, promise, assurance or a representation as to the projected results, future events or performance. Mammoth Scientific, LLC disclaims any obligation to update these forward-looking statements or projections or this document in general.

Investments in the Mammoth Funds will be suitable only for certain financially sophisticated investors who meet certain eligibility requirements, have no need for immediate liquidity in their investment, and can bear the risk of an investment in the Mammoth Funds for an extended period.

There is no guarantee that the investment objectives will be achieved. Moreover, the past performance of the investment team should not be construed as an indicator of future success. All prospective investors are encouraged to consult with their own legal, tax, financial and investment advisors. All investors should make their own determination of whether to make an investment based on their own independent evaluation. Additionally, this document does not include all material terms of the offering. This document is qualified entirely by the Fund’s Operating Agreement, offering documents and other legal and governance documents.

7.21.2021

**PRIVATE COMPANIES AND PRIVATE INVESTMENTS INVOLVE UNIQUE RISKS. YOU SHOULD BE AWARE THAT YOU COULD LOSE YOUR ENTIRE INVESTMENT.**